BLUF is in public beta. Automated sourcing and summaries by the BLUF engine, monitored by our team. Summaries may contain errors — verify important details at the source. Not medical, legal or financial advice. Public beta — automated summaries may contain errors. Full disclaimer
FDA approves injectable gefurulimab for adults with generalized myasthenia gravis
1 OUTLET UNITED STATESONGOING
NOT MEDICAL ADVICE
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
BLUF
The FDA approved injectable gefurulimab, sold as Klygefa, for adults with generalized myasthenia gravis who are anti-acetylcholine receptor positive, MedPage Today reports. The drug blocks complement component 5 activation.
WHAT IS VERIFIED — AND WHAT IS NOT
Source coverage is not proof of every claim. Confirmed means direct support from an official record; corroborated means matching reporting; reported means attributed but not independently verified here. Disputed details remain unresolved.
REPORTED
The FDA approved injectable gefurulimab (Klygefa) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor positive.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
CONFIDENCE: LOW · SOURCE GRADE B6Coverage from 1 independent outlet; no official record is among BLUF's sources yet; officials may be quoted in the reporting. Coverage breadth does not verify every claim; see claim-level sources. What B6 means
Why it matters
The approval makes the treatment an option for eligible adults in the United States.
What happens next
The report does not say when the drug will become available or provide further details about its use.